GlassScriptPhysician profile
Nilesh Mehta
NPI 1649436163
$18,755.26
in general payments reported to CMS, 2019-2025
31 companies · $98.20 in 2025
The $98.20 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $547 · 2021: $1,111 · 2022: $1,605 · 2023: $14K · 2024: $524 · 2025: $98.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $13K · Food and Beverage: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $12,692.19 |
| Food and Beverage | $2,180.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $12,692.19 | 2023 | Evis Exera III Gastrointestinal Videoscope, Evis Exera Lll Colonovideoscope |
| Abbvie INC. | $1,933.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.09 | 2019-2023 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $501.56 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Pfizer INC. | $394.72 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $346.71 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $249.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $218.70 | 2019-2023 | Dificid |
| Janssen Biotech, INC. | $217.60 | 2019-2024 | Stelara, Simponi, Remicade |
| Daiichi Sankyo INC. | $159.94 | 2021-2024 | Injectafer |
| Capsovision, INC. | $151.30 | 2023-2025 | Capsocam Plus |
| Genzyme Corporation | $145.76 | 2022-2024 | |
| Allergan, INC. | $135.78 | 2020 | |
| Boston Scientific Corporation | $119.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.80 | 2019-2023 | Entyvio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $99.79 | 2022-2023 | Ocaliva |
| Celgene Corporation | $77.97 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $73.32 | 2019-2021 | |
| Gilead Sciences, INC. | $72.04 | 2021-2022 | |
| Qol Medical, LLC | $58.30 | 2019 | |
| Ardelyx, INC. | $50.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $41.19 | 2019-2022 | |
| Alfasigma USA, INC. | $35.26 | 2021 | |
| Lilly USA, LLC | $28.97 | 2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $20.37 | 2021 | |
| Concordia Pharmaceuticals INC. | $20.18 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.40 | 2020 | |
| Axonics, INC. | $18.21 | 2022 | |
| Intra-Sana Laboratories | $17.93 | 2021 | |
| Shire North American Group INC | $17.43 | 2019 | |
| Shionogi INC | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.